|
|
|
|
Angiotech - Redefining Success™ - Clinical Trials
Global Locations Site Map Home Search GO About Us Corporate Profile Company History Management Team Corporate Alliances Intellectual Property Focus Markets Focus Markets Overview Wound Closure Technology Medical Devices Technology Pipeline Clinical Trials Patient Education Glossary Investors Investor Overview Corporate Governance Events & Webcasts Quarterly Results Annual Reports...
|
|
|
Angiotech - Redefining Success™ - Technology Pipeline
Global Locations Site Map Home Search GO About Us Corporate Profile Company History Management Team Corporate Alliances Intellectual Property Focus Markets Focus Markets Overview Wound Closure Technology Medical Devices Technology Pipeline Clinical Trials Patient Education Glossary Investors Investor Overview Corporate Governance Events & Webcasts Quarterly Results Annual Reports...
|
|
|
Aroplatin references
Home - Products & Technologies - Cancer Products - Aroplatin Aroplatin references 2006 Dragovich T, Mendelson D, Kurtin S, Richardson K, Von Hoff D, Hoos A.
Oxaliplatin degradation in the presence of chloride: identification and cytotoxicity of the monochloro monooxalato complex.
Am J Vet Res 2000;61:791-795.
Perez-Soler R, Walsh GL, Swisher SG et al.
Raymond E, Buquet...
|
|
|
Allergan
Skip to content Global Locations- Contact Us- Search- About Us- History Leadership Global Locations What We Treat- Eye Care: Dry Eye Glaucoma Other Eye Conditions Neurosciences: Blepharospasm Cervical Dystonia Strabismus Obesity Intervention Medical Aesthetics: Breast Aesthetics Facial Aesthetics Medical Dermatology: Acne Psoriasis Severe Primary Axillary Hyperhidrosis Other Skin...
author: PINT [ www.pint.com ]
|
|
|
Microsoft Word - fluoroplex_cream.doc
June 14, 2001 FLUOROPLEX ® (Fluorouracil) 1% Topical Cream Page 1 of 5 : MATERIAL SAFETY DATA SHEET NFPA Rating: Health: 1 Flammability: 0 Reactivity: 0 Special: 0 TELEPHONE CONTACTS: Product Technical and Medical Information: (800) 433- 8871 Transportation Emergency 24- Hour Response (CHEMTREC): (800) 424- 9300 SECTION 1 : PROD U C T IDENTIFIC A TION Compound Name:...
|
|
|
Microsoft Word - fluoroplex_cream.doc page 5
|
|
|
Microsoft Word - fluoroplex_cream.doc page 4
|
|
|
Microsoft Word - fluoroplex_cream.doc page 3
|
|
|
Microsoft Word - fluoroplex_cream.doc page 2
|
|
|
Microsoft Word - fluoroplex_cream.doc page 1
|
|
|
Allergan
Skip to content Global Locations- Contact Us- Search- About Us- History Leadership Global Locations What We Treat- Eye Care: Dry Eye Glaucoma Other Eye Conditions Neurosciences: Blepharospasm Cervical Dystonia Strabismus Obesity Intervention Medical Aesthetics: Breast Aesthetics Facial Aesthetics Medical Dermatology: Acne Psoriasis Severe Primary Axillary Hyperhidrosis Other Skin...
author: PINT [ www.pint.com ]
|
|
|
Microsoft Word - fluoroplex_solution.doc
June 14, 2001 FLUOROPLEX ® (Fluorouracil) 1% Solution Page 1 of 5 : MATERIAL SAFETY DATA SHEET NFPA Rating: Health: 1 Flammability: 0 Reactivity: 0 Special: 0 TELEPHONE CONTACTS: Product Technical and Medical Information: (800) 433- 8871 Transportation Emergency 24- Hour Response (CHEMTREC): (800) 424- 9300 SECTION 1 : PROD U C T IDENTIFIC A TION Compound Name: FLUOROPLEX ...
|
|
|
Microsoft Word - fluoroplex_solution.doc page 5
|
|
|
Microsoft Word - fluoroplex_solution.doc page 4
|
|
|
Microsoft Word - fluoroplex_solution.doc page 3
|
|
|
Microsoft Word - fluoroplex_solution.doc page 2
|
|
|
Microsoft Word - fluoroplex_solution.doc page 1
|
|
|
Microsoft Word - FLPX Cream PI 2003.DOC
Fluoroplex® ALLERGAN (fluorouracil) 1% Topical Cream DESCRIPTION FLUOROPLEX® (fluorouracil) 1% Topical Cream is an antineoplastic/ antimetabolite product for dermatological use.
Structural Formula: NH N H O O F fluorouracil Chemical Name: 2,4( 1H, 3H)- Pyrimidinedione, 5- fluoro-.
Fluorouracil has been shown to exert mutagenic activity in the...
author: Tran_Ynhu
|
|
|
Microsoft Word - FLPX Cream PI 2003.DOC page 3
author: Tran_Ynhu
|
|
|
Microsoft Word - FLPX Cream PI 2003.DOC page 2
author: Tran_Ynhu
|
|
|
Microsoft Word - FLPX Cream PI 2003.DOC page 1
author: Tran_Ynhu
|
|
|
printmgr file page 23
|
|
|
Angiotech Q3 2007 MDA and Unaudited Financial Statements
Page 1 of 61 ANGIOTECH PHARMACEUTICALS, INC.
· On October 9, 2007, we announced that we intended to file 510( k) clearance documents with the FDA in the fourth quarter of 2007 to market and sell our anti- infective 5- Fluorouracil- coated Central Venous Catheter in the U.
In this study, the Vascular Wrap product was well tolerated, with no adverse events being...
author: gibbott
|
|
|
Angiotech Q3 2007 MDA and Unaudited Financial Statements page 5
author: gibbott
|
|
|
Angiotech Q3 2007 MDA and Unaudited Financial Statements page 3
author: gibbott
|
